The effect of pretreatment with docetaxel (taxotere; RP 56976) on irradiated subcutaneous MA 16/C murine tumors

Journal of Experimental and Clinical Cancer Research

Volumn 18, Issue 2, 1999, Pages 167-172

  Distelmans, W ^a   Storme, G ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Ionizing radiations; Microtubules; Murine tumors; Preclinical; Taxotere

Indexed keywords

DOCETAXEL; ERBULOZOLE; PACLITAXEL; TUBULOZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; INTRAVENOUS DRUG ADMINISTRATION; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; TREATMENT OUTCOME;

ANIMALS; CHEMOTHERAPY, ADJUVANT; FEMALE; INJECTIONS, INTRAVENOUS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; PACLITAXEL; PREMEDICATION; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; SKIN NEOPLASMS; TAXOIDS;

EID: 0032794809     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Steel G.G., Hill R.P., Peckham M.J.: Combined radiation-chemotherapy of Lewis Lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 4:49-52. 1978.
2. Elkind M.M.: Fundamental questions in the combined use of radiation and chemicals in the treatment of cancer. Int. J. Radiat. Oncol. Biol. Phys. 5: 1711-1720. 1979.
3. Bono V.H.: The effect of drug mechanisms of action and pharmacology on their interactions. Int. J. Radiat. Oncol. Biol. Phys. 6:961-962. 1980.
4. Sinclair W.K., Morton R.A.: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Rad. Res. 29: 450-474. 1966.
5. Distelmans W., Van Ginckel R., Vanherck W., Willebrords R., De Brabander M., Wouters L., Van den Winkel P., De Backer G.: Interaction between the microtubule inhibitor tubulozole and gamma-irradiation in murine tumors in vivo. Int. J. Radiat. Onc. Biol. Phys. 16: 177-182. 1989.
6. Distelmans W., Van Ginckel R., Vanherck W., Willebrords R., De Brabander M., Wouters L., Heeres J.: Influence of the synthetic microtubule inhibitor Erbulozole (P.I.N.N.) (R 55 104), a new Tubulozole congener, and gamma-irradiation on murine tumors in vivo. Eur. J. Cancer Clin. Oncol. 25: 1499-1504. 1989.
7. Storme G., Distelmans W., De Neve W., Marcel M.: Interaction between microtubule inhibitors and ionizing radiation. In: Hill B., Bellamy A., eds. Interactions between antitumour drugs and radiation. CRC press: 1990: 107-123.
8. Distelmans W., Van Ginckel R., Vanherck W., Willebrords R., De Brabander M., Mesens J.: Erbulozole (R 55 104 encapsulated into cyclodextrins: has it a combined antitumoral and radioprotective effect? Anticancer Research. 11:253-256. 1991.
9. Distelmans W., Van Ginckel R., Heeres J., Van der Veken L.J.E.: Erbulozole. Drugs of the Future. 16:507-509. 1991.
10. Van Belle S., Distelmans W., Bruynseels J., Vandebroek J., Storme G.: Phase I trial of erbulozole (R 55 104). Anticancer Research. 13: 2389-2392. 1993.
11. Schiff P.H., Fant J., Horwit S.B.: Promotion of microtubule assembly in vitro by taxol. Nature. 2: 665-667. 1979.
12. Schiff P.H., Horwitz S.B.: Taxol stabilizes microtubules in mouse fibroblasts cells. Proc Natl Acad. Sci. USA. 77: 1561-1563. 1980.
13. Schmidt S.M., Coffield R.T., Dykes D.J., Bissery M.C.: Docetaxel induction of S-and G2 + M-phase accumulation and apoptosis in vivo with a human breast tumor model in mice. Proc. Am. Assoc. Cancer Res. 37:438 AB:2990. 1996. 87Th Annual Meeting of the American Association for Cancer Research (AACR), Washington, 20-24/4/96.
14. Tishler R.B., Schiff P.B., Geard C.R., Hall E.J.: Taxol: a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys. 22(3): 613-617. 1992.
15. Choy H., Rodriguez F.F., Koester S., Hilsenbeck S., Von Hoff D.D.: Investigation of taxol as a potential radiation sensitizer. Cancer 71(11): 3774-3778. 1993.
16. Homback N.B., Shen R.N., Sutton G.P., Shidnia H., Kaiser H.E.: Synergistic cytotoxic and antitumor effects of irradiation and taxol on human HeLa cervix carcinoma and mouse B16 melanoma cells. In Vivo. 8(5): 819-823. 1994.
17. Vogt H.G., Kolotas C., Martin T., et al. Simultaneous radiochemtherapy with paclitaxel in non-small cell lung cancer a clinical phase I study. Semin-Oncol. 23(6 Suppl 15): 26-30. 1996.
18. Geard C.R., Jones J.M.: Radiation and taxol effects on synchronized human cervical carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. 29(3): 565-569. 1994.
19. Gupta N., Hu L.J., Deen D.F.: Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 37(4): 885-895. 1997.
20. Guéritte-Voegelein F., Guenard D., Lavell F. et al.: Relationships between the structures of taxol analogues and their antimitotic activity. J. Med. Chem. 34: 992-998. 1991.
21. Bissery M.C., Guenard D., Guéritte-Voegelein F., et al.: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51: 4845-4852. 1991.
22. Choy H., Rodriguez F., Koester S. et al.: Synergistic effects of taxol/taxotere on radiation sensitivity on human tumor cell. Int. J. Radiat. Oncol. Biol. Phys. 24 (suppl 1): 274-275. 1992. AB: 1059, 34th Annual Meeting of the ASTRO, San Diego, 9-13/11/92.
23. Hennequin N., Giocanti N., Favaudon V.: S-phase specificity of cell killing by docetaxel (taxotere) in synchronised HeLa-cells. Br. J. Cancer. 71: 1194-1198. 1995.
24. Bissery M.C., Vrignaud P., Bayssas M., Lavelle F.: Docetaxel (RP 56976, Taxotere) efficacy as a single agent or in combination against mammary tumors in mice. Proc. Am. Assoc. Cancer Res. 135: 327. 1995. AB:1946. 85Th Annual Meeting of the American Association for Cancer Research (AACR), San Francisco, 10-13/4/94.
25. o): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs. 6: 339-368. 1995.
26. SAS Institue Inc. SAS user's guide: basics, version, 5th edition, Cary, NC: SAS Institute Inc.; 1985:1290.